Reviewing Myovant Sciences (MYOV) and Its Peers
Myovant Sciences (NYSE: MYOV) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Myovant Sciences to related companies based on the strength of its earnings, institutional ownership, valuation, risk, analyst recommendations, dividends and profitability.
Insider and Institutional Ownership
79.8% of Myovant Sciences shares are owned by institutional investors. Comparatively, 43.9% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 2.8% of Myovant Sciences shares are owned by insiders. Comparatively, 15.5% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Myovant Sciences and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Myovant Sciences Competitors||131||798||1740||59||2.63|
Myovant Sciences currently has a consensus price target of $22.50, indicating a potential upside of 76.61%. As a group, “Biopharmaceuticals” companies have a potential upside of 12.46%. Given Myovant Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Myovant Sciences is more favorable than its rivals.
This table compares Myovant Sciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Myovant Sciences Competitors||-13,602.79%||-100.87%||-25.29%|
Valuation & Earnings
This table compares Myovant Sciences and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Myovant Sciences||N/A||-$83.44 million||-9.04|
|Myovant Sciences Competitors||$563.95 million||$96.15 million||58.85|
Myovant Sciences’ rivals have higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Myovant Sciences beats its rivals on 6 of the 11 factors compared.
About Myovant Sciences
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.
Receive News & Ratings for Myovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.